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Abstract
The aim of the work was to determine the clinical safety and immunogenicity of immu-
noadjuvant vaccines against influenza (MonoGripol Plus and Grippol® Plus) in 182 preg-
nant women in the II and III trimesters of gestation , and further assessment of fetal 
conditions and infants of the first 6 months of life. Results: It was shown that immuno-
adjuvant vaccines do not have a negative effect on the physiological course of pregnancy 
and the functional state of the fetoplacental complex. In the early postpartum period, the 
rates of physical and neuro-psychological development and the nature of feeding of chil-
dren did not differ from the control group. In pregnant women vaccinated with Grippol® 
plus, the levels of seroprotection to strains of A/H1N1/v are 82.0%, A/H3N2/—88.0%, 
B—88.3% that measure the CPMP criteria and last more than a year . After birth, transpla-
cental antibodies in children in protective values were observed in 52.3–68.9% of cases, 
did not differ from the control group, and disappear after 6 months. Respiratory infec-
tions during the first 6 months of life of infants born from mothers vaccinated against 
influenza registered in 1.8 times less frequently.
Keywords: pregnant women, vaccine against influenza, post-vaccination immunity.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1. Introduction
The reports of Strategic Advisory Group of Experts (SAGE) on Immunization underscore that 
between 7 and 10% of all hospitalized patients with severe influenza are women in the second 
and third trimester of pregnancy. The requirements of pregnant women with influenza infec-
tion for providing medical care in an intensive care unit are 10 times that of other population 
groups diagnosed with influenza [1–4].
Vaccination of pregnant women using the subunit and split influenza vaccines is routinely 
performed in a number of countries of Europe and America for over 20 years, and the vac-
cine efficacy reaches 70–85% [5, 6]. Clinical studies have shown that vaccination of pregnant 
women using modern inactivated influenza vaccines neither affect the course of pregnancy 
and fetal growth nor cause undesirable post-vaccination effects. It was found that vaccination 
of pregnant women using inactivated influenza vaccines leads to 50–63% reduction of flu-
related morbidity among infants up to 6 months of age [7, 8].
The WHO Global Advisory Committee on Vaccine Safety indicates that influenza vaccination 
is a non-alternative approach to safe and effective prevention of influenza in pregnancy [1, 
9, 10]. In Russia, the indications for vaccination of pregnant women using modern vaccines 
are defined within the National Immunization Program Schedule of Russian Federation (RF) 
(order of Ministry of Healthcare of Russian Federation №125n of 21 March 2014). Federal clin-
ical guidelines “Influenza vaccination of pregnant women” and manuals for physicians have 
been published which establish the main vaccination requirements for the primary health 
care in Russia [11–13].
The unfavorable epidemiological situation with influenza that occurred in 2009 has accel-
erated the development and implementation in healthcare practices of adjuvant-containing 
pandemic influenza vaccines such as Fluad (containing squalene) and Arepanrix™H1N1 
(containing AS03—squalene + α-Tocopherol acetate) which confer enhanced immunogenic-
ity [1, 14]. Adjuvants accelerate, change the dynamics of development of the immunity, and 
increase its level and the duration of persistence of post-vaccination antibodies. With the 
help of an adjuvant, durable and solid immunity is achieved by administering small doses of 
antigen and a less number of injections.
In Russia, two adjuvant-containing subunit influenza vaccines have been developed (mon-
ovalent (pandemic) and trivalent preparations). These drugs, in contrast to non-adjuvant 
subunit vaccines against influenza (e.g., Agrippal S1 containing 15 μg strains of influenza 
viruses type A and B), have 5 μg of both strains of the influenza virus and an adjuvant-
immunomodulator polyoxidonium. In clinical trials, immunoadjuvant vaccines demon-
strated high efficacy and safety in children aged 6 months and older and in adults. The 
trivalent adjuvant-based influenza vaccine is used in clinical practice for more than 20 years 
[15–24]. In experimental studies, these vaccines showed no teratogenic effect on the devel-
oping fetus. Despite extensive use of these vaccines for specific prevention of influenza in 
Russia, studies on their safety in pregnancy have not been conducted until recently. The 
information on the effects of adjuvant-containing vaccines on the fetus and post-natal devel-
opment was missing. The information on vaccine immunogenicity for pregnant women at 
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different gestational age, as well as vaccine ability to confer an adequate passive immunity 
to a fetus, was insufficient.
The study aimed at determining clinical safety and immunogenicity of “MonoGrippol Plus” and 
“Grippol® Plus” vaccines in pregnant women in the second and third trimesters of pregnancy 
with assessment of fetal condition and condition of infants during the first 6 months of life.
2. Materials and methods
2.1. Legal basis of the research
The study was carried out according to the protocol which met the National standard of 
Russian Federation—GOST P 52379-2005 “Good Clinical Practice” and the international 
GCP (good clinical practice) standards. Vaccination of pregnant women was carried out 
with adherence to the ethical norms and guidelines of the WHO and Ministry of Health 
care of RF.
Women to be vaccinated and followed up were selected strictly in accordance with a case 
report form that was examined and approved by the Ethics Committee of the Ulyanovsk State 
University (protocol №35 of 14.01.2010).
The observation of pregnant women before and after vaccination was carried out jointly with 
an obstetrician-gynecologist in accordance with requirements of the Order of Ministry of 
Health care and Social Development of RF of 02.10.2009 N 808n “On the approval of the Order 
of providing obstetric and gynecologic care.” Before vaccination, women underwent labora-
tory testing after they have given the informed consent to participate in the study (Figure 1).
During observation and examination of infants, we also adhered to the ethical requirements 
applicable to biomedical studies. Development of the order and scope of studied parameters 
was based on provisions listed in the Order № 370 of Ministry of Healthcare of RF of 28.04.2007.
2.2. Randomization
The study was a randomized, placebo-controlled, single-blind, comparative, parallel-group 
study conducted on pregnant women and infants.
All candidates for study program underwent a preliminary assessment of whether they met 
the protocol inclusion and exclusion criteria (in accordance with the GMP standards).
Eligibility criteria:
1. Healthy pregnant women aged 20–40.
2. Volunteers capable of fulfilling the protocol requirements (i.e., able to fill in the self-obser-
vation diary and turn up for the scheduled visits).
3. Written informed consent of the volunteers to participate in the clinical study.
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Exclusion criteria:
1. History of leukemia, oncologic conditions or positive tests for HIV, hepatitis B and C.
2. Volunteers who had received the immunoglobulin preparations or blood transfusions 
within the last three months prior to the study.
3. Long-term (more than 14 days) administration of immunodepressants or other immu-
nomodulating drugs within the last six months prior to the study.
4. Any confirmed or suspected immunosuppressive or immunodeficiency disorder.
5. History of chronic alcohol abuse and/or substance abuse.
6. Presence of respiratory or cardiovascular insufficiency, hepatic or renal impairment re-
vealed during physical examination or by laboratory tests at visit 1.
7. Severe congenital defects or serious chronic diseases including any clinically significant 
diseases of lungs, kidneys, cardiovascular system, nervous system, psychiatric diseases or 
metabolic disorders confirmed by anamnestic data or objective clinical examination.
Figure 1. An algorithm of laboratory, physical and instrumental investigation.
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8. Presence of acute infectious and/or non-infectious diseases at the time of enrollment in the 
study.
9. Pregnancy via IVF procedure.
2.3. Duration of observation
A total number of pregnant women vaccinated against influenza during the epidemic seasons 
of 2009–2010, 2010–2011, and 2011–2012 were 345 subjects. Of those, the number of women 
and their children participated in an in-depth examination and their assignment to groups 
and subgroups is presented in Table 1.
The frequency of clinical examination and blood collection for laboratory testing in the 
post-vaccination period was based on the gestational age at the start of observation. 
Women vaccinated in the second and third trimesters underwent 7 and 6 examinations, 
respectively.
2.4. Assessment of fetal conditions
Fetometric measurements were carried out using the ultrasound (US) examination during 
pregnancy weeks 21–22 and 33–35 and included determination and calculation of biparietal 
diameter (BPD), fronto-occipital size (FOS), head circumference (HC), abdominal circum-
ference (AC), estimated fetal weight (FW) and the femur length/abdominal circumference 
(FL/AC) ratio. The generally accepted guidelines were followed to evaluate the parameters 
obtained.
2.5. Assessment of infant conditions
Infant observation started from the first hours and days of life (day 2–3) and was conducted 
jointly with a neonatologist at maternity home. The basic signs of functional and morpho-
logical maturity of the newborn (Apgar score), blood work parameters/biochemical profile 
and antibody levels to influenza virus strains have been analyzed. All newborns at maternity 
home underwent neurosonography and cardiac sonography. Basic anthropometric measure-
ments included body weight (BW), body length (BL), head circumference (HC), chest circum-
ference (CC), and height-weight index (Ketle 1).
At the age of 3 and 6 months, the main parameters of physical and neuropsychological devel-
opment and feeding pattern have been recorded.
2.6. Hormonal status in pregnant women
Hormone concentration in pregnant women was measured using the licensed immunoenzyme 
test-systems (IETS) such as “Estradiol-EIA” (LLC “Chema,” Germany), “EIA-Progesterone,” 
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Group I
Pregnant women vaccinated 
with “MonoGrippol Plus”
Group II
Pregnant women vaccinated 
with “Grippol® Plus”
Group III
Pregnant women 
vaccinated with 
“Agrippal S1”
Group IV
Pregnant women who had 
received “Placebo”
Group V
Non-pregnant women, who had 
received
Trimesters of pregnancy MonoGrippol 
Plus
Grippol Plus
II III II III II III II III
Number 
of women 
participated in 
study program
28 15 27 23 27 21 22 19 30 19
Total: 43 50 48 41 49
Average age 
(years)
25.1 ± 0.7 23.3 ± 0.4 27.8 ± 0.6 24.1 ± 0.3 23.1 ± 0.4
Number of 
children born 
to women 
vaccinated 
during 
pregnancy
24 14 27 21 23 19 18 17
Total: 38 48 42 35
Table 1. Study participants’ assignment to observation groups.
Vaccines
72
“EIA-Prolactin,” “EIA-Cortisol” (LLC “Alcor Bio Company, Russia”). Fetoplacental complex 
markers, such as serum alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG) and 
trophoblastic β1-glycoprotein (TBG), were tested using the IETS from CJSC “Vector-Best,” 
Russia.
2.7. Cytokine profile
Serum cytokines were measured to determine levels of interleukin-1α (IL-1α), interleukin-2 
(IL-2), interleukin-4 (IL-4), interferon-γ (IFN-γ), tumor necrosis factor α (TNFα), interleukin-1α 
receptor antagonist (IL-1RA), and interleukin-10 (IL-10). We used a dual cytokine assay to 
measure spontaneous and mitogen-induced cytokine production using a system of sample 
preparation from “Cytokine-Stimul-Best” (CJSC “Vector-Best”, Russia). As the test systems, 
we used standard EIA kits (CJSC “Vector-Best” and LLC “Cytokine”, Russia).
2.8. Humoral immune response to vaccination
Concentration of serum immunoglobulins A, M, G, E and IgG subclasses was determined 
using the appropriate IETS from CJSC “Vector-Best,” Russia. Titers of antibodies to influ-
enza virus strains A and B were measured in the hemagglutination inhibition test (HAI) 
as recommended by the WHO for this kind of studies. As viral antigens, we used the A/
California/7/2009/H1N1/v-like, A/H3N2/(Victoria)-like and B (Brisbane)-like strains pro-
vided by the laboratory of artificial antigens (FSFI “State Research Center at the Institute of 
Immunology” of FMBA, Russia).
Vaccine immunogenicity was determined based on criteria established by the Committee for 
Proprietary Medicinal Products (CPMP) according to the protocol CPMP/BWP/214/96:
1. Seroprotection level (>70%).
2. Seroconversion level or vaccine immunologic activity (>40%).
3. Seroconversion factor or geometric mean fold rise (>2.5).
2.9. Vaccines
All vaccines used in the study were subunit inactivated preparations. Development of 
“MonoGrippol Plus” and “Grippol® Plus” vaccines (LLC “NPO Petrovax Pharm,” Russia) is 
based on a special technology of coupling of highly purified protective influenza virus anti-
gens with a polymeric, water-soluble, high-molecular weight adjuvant polyoxidonium. This 
technology enables a threefold reduction of hemagglutinin (HA) of each viral strain (down 
to 5 μg) in the vaccine compared to the analog subunit, adjuvant-free vaccine “Agrippal S1” 
(“Novartis Vaccines and Diagnostics,” Italy).
“MonoGrippol Plus” contains antigens of only one influenza virus strain, namely A/
California/7/2009/H1N1/v and belongs to the monovalent pandemic influenza vaccines, whereas 
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“Grippol Plus” and “Agrippal S1” additionally contain antigens of other strains, that is, A/H3N2/
(Victoria)-like and B/Brisbane-like (trivalent vaccines).
2.10. Placebo
As a placebo, we used phosphate buffer saline (“GlaxoSmithKline Biologicals”) which is used 
as a diluent for lyophilized vaccines.
2.11. Vaccination
Vaccination of pregnant women was performed in the vaccination room with adherence to 
sanitary and hygiene regulations, with emergency care available at once. Vaccine prepara-
tions were injected intramuscularly as a single-dose of 0.5 mL in the upper third of the arm 
(deltoid muscle).
2.12. Evaluation of vaccination safety
After an injection, the woman was observed for 40 min for the adverse reaction(s), which were 
scored to categorize reactions as described in Table 2.
Local reactions
0—absent Absence of symptoms
1—mild Hyperemia up to 50 mm in diameter or infiltrate up to 25 mm 
in diameter
2—moderate Hyperemia over 50 mm in diameter or infiltrate 26–50 mm in 
diameter
3—severe Infiltrate over 50 mm in diameter
Systemic reactions
0—absent Absence of symptoms
1—mild Presence of mild symptoms
2—moderate Symptoms which markedly impair normal daily activity
3—severe Symptoms which interfere with normal daily activity
Fever
0—absent ≤37°C
1—mild >37°C to ≤37.5°C
2—moderate >37.6°C to ≤38.5°C
3—severe >38.6°C
Table 2. Assessment of undesirable post-vaccination reactions.
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All possible changes in the well-being and health state were recorded in the case report form 
(CRF) and self-observation diary (SOD) which the women continued to fill in on a daily basis 
throughout the first month of the follow-up.
2.13. Statistical analysis
Statistical analysis of samples which did not follow a normally distributed pattern was carried 
out using the non-parametric tools or parametric methods when the samples followed a nor-
mal distribution. We used the applied software package “Microsoft Excel” with the “AtteStat” 
application (version 10.10.2.). The differences were considered significant at p < 0.05.
3. Results and discussion
3.1. Particulars of the course of pregnancy in women vaccinated with “Grippol® Plus”
Although many pregnant women had a history of somatic diseases before they entered the 
study, as a rule, no exacerbation of pre-existing disease has been observed. The most com-
monly encountered illness was a mild hypochromic anemia (60.5, 70.0, 61.3, and 60.9% of 
pregnant women in group I–IV, respectively). Markers of chronic urogenital infection were 
detected fairly often (44.2% in group I, 46.0% in group II, 59.1% in group III, and 41.5% in 
group IV). Also, the syndrome of vegetative dystonia (20.9% in group I, 38.0% in group II, 
20.5% in group III, and 29.3% in group IV) and altered allergic response (16.3% in group I, 
20.0% in group II, 18.2% in group III, and 19.5% in group IV) had been observed. All women 
had approximately the same frequency of cases of threatened miscarriage in the past (53.5% 
in group I, 48.0% in group II, 47.7% in group III, and 51.2% in group IV). Therefore, clinical 
condition of pregnant women was comparable among the groups [25].
3.1.1. Clinical course of the post-vaccination period
Evaluation of the clinical course of the post-vaccination period has shown that it was asymp-
tomatic in 58.1% of women from group I, 60.0% from group II, 54.5% from group III, and 
60.9% from group IV (p > 0.05). It came under notice that in groups I, II, and III, women vac-
cinated in the third trimester of pregnancy developed the post-vaccination local and systemic 
undesirable effects significantly less often than women vaccinated in the second trimester (p < 
0.05 to p < 0.01). The local symptoms occurred in the first few days after vaccination included 
pain, hyperemia, and infiltration at the site of injection. Such reactions occurred more often 
in pregnant women immunized with trivalent vaccines (group II—8.0%, group III—10.4%) 
than in women from placebo group (4.9%), (p < 0.05). It was noted that pregnant women from 
group I developed no or minimal systemic adverse reactions (nausea, fatigability, dizziness or 
myalgia) where intensity was significantly lower compared to that in women vaccinated with 
trivalent vaccine, namely group I—6.9% (p < 0.05 versus group II), group II—12.0%, group 
III—10.4%, and group IV—10.2% [26, 27].
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3.1.2. Clinical blood analysis
In the late (8–30 days) post-vaccination period, no local post-injection reactions have been 
reported in either group. Systemic reactions included frequent complaints on increased fati-
gability and headaches in women from group III (p < 0.05). With regard to other symptoms, 
the groups did not differ significantly between each other and the placebo group (group 
I—9.3%, group II—14.0%, group III—12.5%, and group IV—12.2%). All symptoms were of a 
transient nature and required no medication management [26, 27].
Analysis of complete blood count has shown that for the majority of formed elements, cell 
counts did not differ from normal values in both pre-vaccination and post-vaccination periods. 
Occasional differences were mostly related to the particulars of the pregnancy period. Analysis 
of basic metabolic panel performed in dynamics on day 7 and day 30 of the post-vaccination 
period in each group also did not reveal significant abnormalities which could reflect changes 
in the metabolic homeostasis (p > 0.05). Small changes in creatinine level (minimal value in 
group III at day 30 post-vaccination—58.04 ± 1.57 μmol/L) and alkaline phosphatase (AP) (max-
imum value in group III at day 30 post-vaccination—86.23 ± 7.84 IU/L) are not remarkable and 
fall within the average normal values, attesting to normal variability of this parameter [28, 29].
3.1.3. Lipid metabolism
Analysis of lipid panel obtained 30 days post-vaccination has shown that in all groups, the 
parameters of lipid/cholesterol metabolism are not significantly altered, and remain within 
physiological variations [12, 13].
3.1.4. Hormonal profile
Analysis of hormonal profile among vaccinated women has revealed only the intra-group 
changes in hormone levels which are not so much related to vaccination but rather are due to 
the gestational age.
Significant differences in prolactin, progesterone, estradiol, and cortisol serum levels were 
observed in women of different gestational age regardless of whether they received mon-
ovalent or trivalent influenza vaccine or placebo (p < 0.05). Therefore, it can be affirmed 
that, despite certain differences in the composition of influenza vaccines used in the study, 
there are no hormonal changes which could have influenced the state of the fetoplacental 
unit [12, 13].
3.1.5. Humoral immunity
Serum levels of immunoglobulins measured immediately after vaccination and on day 7 
post-vaccination were comparable in pregnant women immunized with different influenza 
vaccines. At day 30, post-vaccination pregnant women who had received the monovalent 
influenza vaccine demonstrated higher IgA levels (2.56 ± 0.27 mg/mL) compared to women 
vaccinated with trivalent preparations (1.61 ± 0.09 mg/mL in group II, 1.34 ± 0.11 mg/mL in 
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group III, and 1.14 ± 0.14 mg/mL in group IV) (p < 0.01 to p < 0.001). Despite the above differ-
ences, the antibody levels reflect normal serum IgA variations. Despite the established differ-
ence, the IgA content in all comparison groups was recorded within the physiological norm. 
Levels of IgM and IgG antibodies did not differ significantly between the groups.
Some variations in the IgG subclasses (1, 2, 3, 4) in the early and late post-vaccination periods 
were found. However, these variations remained within the acceptable range. In pregnant 
women with a history of allergic diseases, vaccination against influenza had no subsequent 
effect on serum total IgE levels.
3.1.6. Cytokine profile
It was noted that all pregnant women vaccinated with different vaccine preparations had 
elevated levels of mitogen-stimulated IL-1α at day 7 post-vaccination. By day 30, concen-
tration of IL-1α remained elevated as compared to placebo control (p < 0.05) although was 
significantly lower than in vaccinated non-pregnant women (p < 0.01). No changes in the IL-2 
and TNFα levels have been observed in vaccinated pregnant women although were also sig-
nificantly higher than in non-pregnant women (p < 0.01). The IL-1RA values in a spontaneous 
cytokine production assay were significantly elevated only after vaccination with trivalent 
preparations by day 7 (group II) and by day 30 (groups II and III) post-vaccination (p < 0.01). 
At the same time, following mitogen stimulation, no significant changes in the IL-2 concentra-
tion have been found in any group. All pregnant women demonstrated significant increase 
in the IL-IRA and IL-10 following mitogen stimulation regardless of the type of vaccine that 
reflected the mechanism of physiological control of immune activation.
The IL-4 levels were most stable, with no significant dynamic changes among the groups. The 
only exception was a subgroup of women immunized with a non-adjuvanted trivalent vaccine 
in different trimesters of pregnancy. It was noted that by day 7 post-vaccination, a higher level of 
stimulated IL-4 was found in vaccinated women in the third trimester of pregnancy (6.85 ± 0.11 
pg/mL in group III) as compared to pregnant women who had received the adjuvant-contain-
ing vaccine during the same period (2.95 ± 0.09 pg/mL in group II) (p < 0.05). Subsequently (on 
day 30 post-vaccination), such differences between the groups could not be found.
Pregnant women had lower IFNγ levels in the mitogen-stimulated cytokine production 
assay (881.86 ± 92.93 pg/mL in group I, 784.17 ± 65.03 pg/mL in group II, 854.89 ± 68.71 
pg/mL in group III, and 790.30 ± 45.55 pg/mL in group IV) than the non-pregnant women 
(1419.60 ± 69.45 pg/mL in group V) which reflected a natural background level of physiologi-
cal immune response (p < 0.05). At the same time during the first 7 days, post-vaccination 
elevated IFNγ was detected only in pregnant women who had received the polymer-subunit 
vaccines (6.47 ± 1.68 pg/mL in group I and 5.89 ± 1.08 pg/mL in group II) as compared to 
group III (3.03 ± 0.39 pg/mL) (p < 0.05). These differences were short-lived, and by day 30, 
post-vaccination was undetectable [30].
Therefore, the overall picture of cytokine profile in pregnant women had a trend characteristic 
of physiologic immunosuppression in pregnancy, that is, moderately elevated IL-IRA and 
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IL-10 and the absence in the post-vaccination period of significantly elevated anti-inflammatory 
cytokines in the mitogen-stimulation cytokine production assay. Nonetheless, the adjuvanted 
subunit vaccines had certain differences in their ability to influence cytokine secretion and 
short-term elevation of IFNγ which is most prominent in women in the second trimester of 
pregnancy that may reflect active involvement of the Th1-mediated mechanisms of post-vac-cination immunity. Use of non-adjuvanted vaccines leads to immune processes in the early 
post-vaccination period which are accompanied by increased IL-4 synthesis by blood leuko-
cytes (a sign of Th2-mediated activation) especially in women vaccinated in late pregnancy. The indirect evidence in favor of this suggestion is the absence of significance changes in 
the IFNγ levels in the early and late post-vaccination periods. All found changes of param-
eters recorded in different groups of vaccinated women remained within an acceptable range 
of variation. Also, no changes pertaining to destabilization of regulation and functioning of 
immune system due to influenza vaccination of pregnant women have been found [31].
3.2. Effect of vaccination of pregnant women using “Grippol® Plus” influenza vaccine on 
the antenatal fetal development
3.2.1. Fetoplacental complex
Monitoring of fetal development was carried out using a complex of measures, which 
included analysis of markers of fetoplacental complex and ultrasound fetometry. In all groups 
of women in the early and late post-vaccination period, no changes in the basic parameters 
of embryo/fetogenesis (AFP, hCG, TBG) have been found (Table 3). Changes in the above 
parameters did not depend on the type of influenza vaccine used and corresponded to the ges-
tational age (second and third trimesters of pregnancy). Thus, for example, the TBG level in all 
Parameter Group I
“MonoGrippol 
Plus”
(n = 43)
Group II
“Grippol® Plus”
(n = 50)
Group III
“Agrippal S1”
(n = 48)
Group IV
“Placebo”
(n = 41)
In 7 days TBG
Ng/mL
97.93 ± 20.97 72.69 ± 11.89 88.04 ± 15.46 92.69 ± 20.88
AFP
IU/mL
60.05 ± 13.39 69.59 ± 7.62 81.09 ± 17.88 75.41 ± 10.36
hCG
IU/mL
36.51 ± 4.62 39.74 ± 8.22 40.43 ± 3.10 36.15 ± 2.48
In 30 days TBG
Ng/mL
124.85 ± 14.43 109.17 ± 10.81 118.21 ± 13.99 110.35 ± 13.12
AFP
IU/mL
98.65 ± 8.33 100.43 ± 11.01 110.84 ± 11.19 115.29 ± 9.92
hCG
IU/mL
29.52 ± 3.62 33.84 ± 7.55 29.24 ± 5.20 28.95 ± 1.88
Note: p > 0.05 for differences between groups.
Table 3. Fetal complex markers in pregnant women vaccinated against influenza (M ± m).
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groups (including placebo control) of women vaccinated in the second trimester of pregnancy 
was significantly lower than in the third trimester (p < 0.05 to p < 0.01). A direct relationship 
was found between the TBG and AFP concentrations (r = 0.60; p < 0.05) with TBG levels rising 
as pregnancy progresses (p < 0.001). The hCG levels were dropping during the follow-up and 
inversely correlated with the TBG levels (r= -0.50; p < 0.01). All serum markers had no devia-
tions from the reference values and reflected physiological changes in pregnancy [32].
3.2.2. Fetometry
Fetometry performed in the second (21–22 weeks) and third (33–35 `) trimester of pregnancy 
failed to reveal differences among the groups of pregnant women (Table 4).
Therefore, study results indicate that vaccination of pregnant women using the adjuvant-
containing influenza vaccines “MonoGrippol Plus” and “Grippol® Plus” has no effect on the 
intrauterine fetal development. Changes of the basic parameters of fetoplacental unit are com-
parable between the groups and reflect physiological changes during fetal growth.
3.3. Pregnancy outcomes in women vaccinated with “MonoGrippol Plus” and “Grippol® 
Plus” influenza vaccines
In the majority of cases (85.4–90.7%), pregnancy resulted in physiologic birth (Table 5). In a 
fraction of women, their pregnancy terminated prematurely with the birth of preterm babies 
(between 2.0 and 8.3%) which corresponds to the preterm birth rate in the Ulyanovsk region 
of Russia (3.7–5.8%) where the study was taking place. Such outcome was due to the obstetric 
pathology which was unrelated to prior vaccination. Also, cases of birth of babies with perina-
tally acquired neurological impairment were mostly associated with gestational immaturity 
(7.3–10.4%). A fraction of babies had the intrauterine infection-like syndrome (2.0–6.3%) and 
developmental abnormalities and defects in 2.0–4.9% of cases (3.8–5.9% across the Ulyanovsk 
region) [33]. Owing to the above abnormalities, such babies were excluded from further study.
3.4. Particulars of development of up to 6 month old infants born to mothers vaccinated 
during pregnancy with “MonoGrippol Plus” and “Grippol® Plus” influenza vaccines
3.4.1. Apgar scale
The early neonatal period of infants born to mothers vaccinated during pregnancy had a compa-
rable dynamics between the groups. It was shown that, immediately after birth, the number of 
babies with Apgar score of 8–9 points was similar between the groups (group I—92.1%, group 
II—87.5%, group III—80.9%, and group IV—94.3%) which attests to the overall good functional 
maturity. The period of adaptation in newborns passed without complications [34, 35].
3.4.2. Feeding
The feeding of infants born to mothers vaccinated with different influenza vaccines did not 
differ significantly between the groups. The highest number of nursing mothers (100%) dur-
ing the neonatal period was observed in groups I and IV and was somewhat lower in groups 
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Clinical groups Gestational age Parameter
BPD (mm) FOS (mm) HC (mm) AC (mm) Fetal weight (g)
 
FL
 
___
 
AC
 × 100 (%)
Group I
“MonoGrippol Plus” 
(n = 43)
21–22 weeks 53.18 ± 3.20 73.87 ± 8.11 188.12 ± 13.72 162.81 ± 17.08 527.10 ± 92.31 21.54 ± 0.57
33–35 weeks 87.81 ± 5.52 111.67 ± 12.9 313.01 ± 24.18 311.60 ± 18.57 2539.40 ± 437.10 22.04 ± 0.44
Group II
“Grippol® Plus”
(n = 50)
21–22 weeks 54.04 ± 2.70 70.07 ± 7.42 183.90 ± 11.86 170.11 ± 15.98 504.70 ± 96.01 19.49 ± 0.86
33–35 weeks 89.11 ± 5.31 109.80 ± 14.20 304.21 ± 38.73 295.90 ± 21.07 2489.70 ± 367.30 23.13 ± 0.78
Group III
“Agrippal S1”
(n = 48)
21–22 weeks 52.56 ± 2.62 68.55 ± 8.12 180.87 ± 18.66 175.44 ± 16.08 489.50 ± 110.10 20.26 ± 0.93
33–35 weeks 81.49 ± 6.53 106.12 ± 11.40 301.01 ± 21.74 298.30 ± 33.15 2595.2 ± 455.1 22.96 ± 1.04
Group IV
“Placebo”
(n = 41)
21–22 weeks 52.01 ± 3.9 67.22 ± 9.02 181.01 ± 15.31 178.79 ± 13.9 497.72 ± 138.03 20.99 ± 1.02
33–35 weeks 82.77 ± 7.71 103.07 ± 8.33 299.82 ± 28.53 301.02 ± 29.34 2607.7 ± 631.0 22.73 ± 1.38
Note: p > 0.05 for differences between groups.
Table 4. Ultrasound-fetometry data in pregnant women vaccinated against influenza (M ± m).
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II and III (85.4 and 92.9%, respectively) (p > 0.05). Further onwards, the number of infants 
receiving only breast milk gradually diminished (92.1% at 3 months and 65.8% at 6 months in 
group I; 85.4% at 3 months and 72.9% at 6 months in group II; 83.3% at 3 months and 69.0% at 
6 months in group III; and 88.6% at 3 months and 60.0% at 6 months in group IV) (p > 0.05). 
Therefore, vaccination of women with subunit adjuvanted influenza vaccines during preg-
nancy has no further impact on lactation and duration of breastfeeding.
3.4.3. Body weight and length
Parameters of physical development of infants of the first 6 months of life from different 
groups were generally comparable. Body weight and body length at different time points were 
within the percentile rank (25-50-75). The Ketle 1 index in group I newborns was 65.1 ± 0.67, in 
group II—63.8 ± 1.22, in group III—65.5 ± 1.72, and in group IV—67.1 ± 1.03 (p > 0.05).
In the majority of cases, the proportionality of physical development among infants in their 
first few months of life had the average values of harmonious development, namely 65–74% in 
group I, 70–76% in group II, 69–81% in group III, and 69–76% in placebo group (p > 0.05). The 
infants with the average values below harmonious development were found equally often (14–
22% in group I, 12–16% in group II, 12–19% in group III, and 18–21% in group IV). The infants 
with the average values above harmonious development (6–22% in group I, 10–17% in group II, 
7–12% in group III, and 6–15% in group IV) were considered as a variant of body constitutional 
norm (p > 0.05). Infants with a disproportional physical development have not been found.
Parameter Group I
“MonoGrippol 
Plus”
(n = 43)
Group II
“Grippol® Plus”
(n = 50)
Group III
“Agrippal S1”
(n = 48)
Group IV
“Placebo”
(n = 41)
Women Physiological 
birth
39 (90.7%) 48 (96.0%) 43 (89.5%) 35 (85.4%)
Miscarriage 0 1 (2.0%) 1 (2.1%) 1 (2.4%)
Premature birth 4 (9.3%) 1 (2.0%) 4 (8.3%) 3 (7.3%)
Infants Without 
pathology
38 (88.4%) 46 (92.0%) 42 (87.5%) 33 (85.4%)
Birth of 
babies with 
abnormalities or 
developmental 
defects
1 (2.3%) 1 (2.0%) 2 (4.2%) 2 (4.9%)
Perinatal CNS 
lesions
4 (9.3%) 3 (6.0%) 5 (10.4%) 3 (7.3%)
Intrauterine 
infection-like 
syndrome
2 (4.6%) 1 (2.0%) 4 (6.3%) 2 (4.9%)
Note: p > 0.05 for differences between groups.
Table 5. Outcomes of pregnancy and birth in women vaccinated against influenza.
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Therefore, our results attest to the sufficiency of basic criteria for infant development and 
reflect the population maturity in terms of their physical development regardless of vaccina-
tion of their mothers during pregnancy with different influenza subunit vaccines.
3.4.4. Neuropsychological development
Parameters of neuropsychological development (NPD) of children born to vaccinated mothers 
did not differ significantly from those of the placebo group. Overall, no changes of NPD have 
been observed in 81.6% of group I infants in their first 6 months of life who had been born to 
mothers vaccinated during pregnancy with a monovalent influenza vaccine. In other clinical 
groups, this parameter was 83.3% (group II), 78.6% (group III), and 77.1% (group IV) (p > 0.05). 
Within the structure of occasional NPD disorders, there were conditions which number did 
not exceed the average statistical rate of neurological pathology in a given pediatric age group.
It was noted that infants born to women vaccinated during pregnancy with trivalent influenza 
vaccines were 1.8-times less likely to develop non-influenza respiratory infections within the 
first 6 months of life as compared to infants from placebo control group (Figure 2).
3.5. Immunogenicity of adjuvanted influenza vaccine “Grippol® Plus” in pregnant women 
vaccinated during different trimesters of pregnancy
In this study, the level of post-vaccination antibodies to influenza virus was evaluated only 
in a group of pregnant women and non-pregnant women vaccinated with a trivalent adju-
vanted influenza vaccine with the aim of revealing the features of the effect of pregnancy on 
the synthesis of antibodies. Since it has been already proven that the introduction of subunit 
unadjuvanted vaccines in pregnant women is accompanied by the formation of antibodies to 
the influenza virus in values not differing from those in non-pregnant ones, it seemed to us 
interesting to investigate the interaction of the immunoadjuvant preparation with the tran-
siently altered immune status of the pregnant woman [36].
Figure 2. Incidence of morbidity due to non-influenza respiratory infections in infants during their first 6 months of life. 
Note: *- p < 0.05 for differences between groups I, II, III and group IV.
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It was found that a part of women before immunization had a seroprotective (≥1:40) baseline 
antibody level to vaccine strains of influenza virus (Table 6). In all examined women, the 
antibody titer was higher to influenza virus B (22.2% of women in the second trimester, 26.1% 
in the third trimester and 25.7% in non-pregnant women). This is probably due to the dura-
tion of its circulation in the population and the formation of natural immunity. It should be 
noted that none of the participants in the study was vaccinated before and did not confirm an 
acute illness caused by the influenza virus. One month after vaccination, women of all groups 
demonstrated a significant rise in antibody titer that fully met one of the CPMP criteria. In the 
post-vaccination period, the antiviral antibody titer gradually declined reaching a significant 
difference against baseline by 3 months postpartum in women vaccinated in the second and 
third trimesters. The observed difference referred only to viral strain A/H1N1/v (p < 0.05). It is 
possible that the loss of antibodies to a pandemic strain is associated with the peculiarities of 
the formation of immunity after its first administration. Other authors have shown that spe-
cific antibodies to this strain in the post-vaccination period can be synthesized at lower values 
and therefore be accompanied by their faster loss. At 6 and 12 months post-vaccination, there 
was a marked regression of seroprotection level with regard to antibody titer against strains 
A/H1N1/v, A/H3N2/and B in women vaccinated during pregnancy in the second and third 
trimesters (p < 0.01). Such trend was also traced in a group of non-pregnant women; however, 
the changes were less remarkable, with a fairly significant fraction of subjects having a high 
level of protective antibodies. Similar dynamics of post-vaccination antibodies were noted in 
pregnant women vaccinated with subunit non-adjuvanted influenza vaccine [37].
The rate of development and intensity of protective immunity include the level and fac-
tor of seroconversion across all influenza virus strains. Those were compared between the 
groups, and it was found that their values met the CPMP criteria (Table 7). The majority 
of data obtained did not differ between the groups. One exception was the seroconversion 
factor for strain B in pregnant women vaccinated in the third trimester of pregnancy (5.1) 
when it was compared with the matching parameter in the non-pregnant women group 
(6.9) (p < 0.05).
The dynamics of influenza antibody (AB) titers based on the geometric mean titer (GMT) 
reflect the decline of antibody level with time in the post-vaccination period (Table 8). It 
was noted that at one month post-vaccination, the value of GMT AB to A/H1N1/v strain in 
women vaccinated in the second trimester of pregnancy was significantly lower (49.12 ± 0.29) 
compared to subjects vaccinated in the third trimester of pregnancy (60.99 ± 0.25) (p < 0.05). 
During all subsequent periods, this parameter showed no differences with regard to the tri-
mester of pregnancy.
Pregnant women vaccinated in the third trimester of pregnancy showed at 3 months post-
vaccination and throughout the follow-up period lower GMT AB titers to strain B compared 
to the non-pregnant women (p < 0.05 to p < 0.01). Similar trend was traced in women of the 
same group with regard to all influenza virus strains at 6 months postpartum compared to the 
non-pregnant women (p < 0.05 to p < 0.01).
Therefore, the post-vaccination immune response in women vaccinated with a trivalent adju-
vanted influenza vaccine at different times of pregnancy, during the first month, did not differ 
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Periods of 
observation
Second trimester (n = 27) Third trimester (n = 23) Non-pregnant women (n = 19)
A/H1N1/v A/H3N2/ B A/H1N1/v A/H3N2/ B A/H1N1/v A/H3N2/ B
Seroprotection 
level (AB 
titer ≥ 1:40)
(%)
Before 
vaccination (V)
3.7 11.1 22.2 8.7 13.0 26.1 2.6 14.1 25.7
1 month post-V 77.0* 88.9* 85.2* 87.0* 87.0* 91.3* 83.1* 90.2* 94.4*
3 months 
post-V
74.8 88.4 84.2 — — — 80.6 88.7 92.0
6 (3) months 
post-V
2–3 days 
postpartum
74.1 81.5 77.8 62.0 76.2 71.4 78.5 83.1 88.2
9 (6) months 
post-V
3 months 
postpartum
57.7 × 69.2 65.4 57.1 × 71.4 62.0 71.4 78.6 72.8
12 (9) months 
post-V
6 months 
postpartum
48.2 ∇∇/× 65.4 ∇∇ 57.7 ∇∇/× 50.0 ∇∇/× 61.1 ∇∇ 55.6 ∇∇/× 67.6 ∇ 72.5 ∇ 69.1 ∇∇
Note: Time period elapsed since the moment of vaccination of women in the third trimester of pregnancy (group II) is given in brackets.
*: p < 0.01—the intra-group difference for the second/third trimesters of pregnancy; non-pregnant in-between pre-vaccination and 1 month post-vaccination.
∇: p < 0.05; ∇∇: p < 0.01—the intra-group difference for the second/third trimesters of pregnancy; non-pregnant in-between 1 month and 12 (9) months post-vaccination.
×: p < 0.05; ××: p < 0.01—difference between the second/third trimesters of pregnancy group and non-pregnant group.
Table 6. Seroprotection level in pregnant women vaccinated with “Grippol® Plus,” allowing for trimester of pregnancy.
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Parameter Second trimester (n = 27) Third trimester (n = 23) Non-pregnant women (n = 19)
A/H1N1/ A/H3N2/ B A/H1N1/ A/H3N2/ B A/H1N1/ A/H3N2/ B
Seroconversion 
level (%)
70.4 77.8 74.1 69.6 78.3 65.2 71.5 81.1 70.3
Seroconversion 
factor
6.5 7.2 6.5 7.1 6.5 5.1* 6.8 7.6 6.9
Note: *p < 0.05 for difference between the third trimester group and non-pregnant group.
Table 7. Seroconversion level and seroconversion factor in pregnant women vaccinated with “Grippol® Plus,” allowing for the trimester.
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Periods of 
observation
Second trimester (n = 27) Third trimester (n = 23) Non-pregnant (n = 19)
A/H1N1/v A/H3N2/ B A/H1N1/v A/H3N2/ B A/H1N1/v A/H3N2/ B
Geometric 
mean 
antibody 
titer
(log2GMT AB)
Before 
vaccination 
(V)
7.54 ± 0.17 8.79 ± 0.23 13.96 ± 0.26 8.60 ± 0.23 10.62 ± 0.24 14.36 ± 0.25 8.02 ± 0.15 9.12 ± 0.21 14.19 ± 0.21
1 month 
post-V
49.12 ± 0.29 63.49 ± 0.28 90.96 ± 0.36 60.99 ± 0.25
*
68.81 ± 0.26 73.08 ± 0.24 52.12 ± 0.22 59.47 ± 0.24 81.11 ± 0.37
3 months 
post-V
47.87 ± 0.27 55.85 ± 0.26 65.15 ± 0.35 — — — 51.31 ± 0.24 57.73 ± 0.31 73.88 ± 0.26
6 (3) months 
post-V
2–3 days 
postpartum
41.04 ± 0.23 44.33 ± 0.22 47.87 ± 0.32 41.34 ± 0.30 45.64 ± 0.25 42.72 ± 0.30
×
48.56 ± 0.22 55.53 ± 0.24 63.13 ± 0.36
9 (6) months 
post-V
3 months 
postpartum
30.64 ± 0.23 29.83 ± 0.22
××
32.32 ± 0.29 30.72 ± 0.31 31.75 ± 0.32
×
26.92 ± 0.35
××
44.82 ± 0.25 51.79 ± 0.23 57.71 ± 0.31
12 (9) months 
post-V
6 months 
postpartum
21.67 ± 0.24
∇∇/×
24.10 ± 0.26
∇∇/××
25.42 ± 0.25
∇∇/××
20.79 ± 0.34
∇∇/×
25.19 ± 0.33
∇∇/××
19.24 ± 0.35
∇∇/××
38.17 ± 0.26
∇
44.47 ± 0.21
∇
50.03 ± 0.28
∇∇
Note: Time period elapsed since the moment of vaccination of women in the third trimester of pregnancy is given in brackets.
*: p < 0.05—for difference between the second trimester/third trimester groups.
∇: p < 0.05; ∇∇: p < 0.01—the intra-group difference for the second/third trimesters of pregnancy; non-pregnant between 1 month and 12 (9) months post-vaccination.
×: p < 0.05; ××: p < 0.01—for difference between the second trimester group, third trimester group and non-pregnant group.
Table 8. Geometric mean antibody titer in pregnant women vaccinated with “Grippol® Plus,” allowing for the trimester.
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from that in vaccinated non-pregnant women and fully met the CPMP criteria. The level of 
antibodies to strain A/H1N1/v following administration of a trivalent vaccine was nearly the 
same as with vaccination of pregnant women with the monovalent, subunit, adjuvanted vac-
cine [38, 39]
With time the postpartum women demonstrated a more pronounced reduction of seropro-
tection level, especially against the A/H1N1/v strain. After 6 months postpartum, the rate 
of regression of seroprotection level in subgroups of vaccinated pregnant women (taking 
into account the gestational age) has increased 1.6–1.7-fold (A/H1N1/v), 1.4-fold (A/H3N2) 
and 1.5- to 1.6-fold (B), whereas in the non-pregnant women group same parameter was 
1.2-fold (A/H1N1/v), 1.2-fold (A/H3N2) and 1.4-fold (B), respectively. This trend was in line 
with dynamic reduction of the MGT AB values during the last months of the follow-up [38]. 
Consequently, the existing physiological immunological changes in the immune system 
during pregnancy may affect the formation and preservation of post-vaccination antibodies 
to strains of influenza virus when using subunit immunoadjuvant vaccines. However, this 
assumption should be confirmed by new data research.
3.6. Immunologic effectiveness of vaccination of pregnant women using “Grippol® Plus” 
influenza vaccine in mother-infant pairs
Analysis of transplacental immunity in the first months of life of infants born to women vac-
cinated during pregnancy with “Grippol® Plus” vaccine has shown that the level of seropro-
tection against influenza virus strains significantly differed only in the mother-infant pairs 
from the group of subjects vaccinated in the second trimester of pregnancy (p < 0.05), while 
no differences in the number of seroprotected infants have been found (p > 0.05) (Table 9). 
At 3 months after birth all infants, regardless of the time of their mothers’ vaccination, dem-
onstrated a significant reduction of protective titers of transplacental antibodies to vaccine 
strains of influenza virus as compared to their antibody titers obtained at birth and antibody 
titers in their mothers (p < 0.01). Further onwards, protective antibodies to vaccine strains 
of influenza virus completely vanished, and among the 6-month infants, the titer dropped 
to zero in both groups [40]. It should be noted that by 3 months of life, the rate of regression 
of antibody titer was higher in the subgroup of infants born to mothers vaccinated in late 
pregnancy, namely 2.8-fold higher for A/H1N1/v, 2.6-fold higher for A/H3N2/, and 4.0-fold 
higher for B strain.
Therefore, 52.3–61.9% of babies born to women vaccinated during pregnancy with “Grippol® 
Plus” vaccine had protective antibody levels against vaccine influenza strains at the time of 
their birth. This level of protection significantly declined with time and by 3 months of life 
remained at a protective level in only 14.2–24.0% of infants. At the age of 6 months, protec-
tive titers of maternal antibodies completely vanished in all infants. Infants born to women 
vaccinated in the second trimester of pregnancy had higher activity of protective antibodies 
and lower rate of reduction of seroprotection level which attests to a better preservation of 
the post-vaccination transplacental immunity. Thus, the advantage of vaccination of preg-
nant women with the use of immunoadjuvant subunit vaccine in the II trimester of gestation 
was revealed.
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Observation periods Second trimester Third trimester
A/H1N1/v A/H3N2/ B A/H1N1/v A/H3N2/ B
M I M I M I M I M I M I
Seroprotection 
level (%)
(AB titer > 
1:40)
Day 2–3 postpartum/
newborns
74.1 55.5 × 81.5 59.3 × 77.8 60.2 × 62.0 52.3 76.2 61.9 71.4 57.1 ×
At 3 months 
postpartum/3 months 
old
57.7 20.0  
××/⊗⊗
69.2 24.0 
××/⊗⊗
65.4 20.0 
▲××/⊗⊗
57.1 19.0 
××/⊗⊗
71.4 23.8 
××/⊗⊗
62.0 14.2 
××/⊗⊗
At 6 months 
postpartum/6 months 
old
46.2 0 ⊗⊗ 65.4 0 ⊗⊗ 57.7 0 ⊗⊗ 50.0 0 ⊗⊗ 61.1 0 ⊗⊗ 55.6 0 ⊗⊗
Geometric 
mean 
antibody titer
(log2GMT AB)
Day 2–3 postpartum/
newborns
41.04 ± 0.23 25.85 ± 0.29 
×
44.33 ± 
0.22
27.22 
±0.26 ×
47.87 
±0.32
30.94 
±0.31
41.34 
±0.30
23.59 
±0.28 ×
45.64 
±0.25
26.91 
±0.25 ×
42.72 
±0.30
25.19 
±0.28 ×
At 3 months 
postpartum/3 months 
old
30.64 ± 0.23 11.30 ± 0.26 
××/⊗⊗
29.83 ± 
0.22
13.86 
±0.24 
××/⊗⊗
32.32 
±0.29
13.19 
±0.32 
××/⊗⊗
30.72 
±0.31
13.46 
±0.25 
××/⊗⊗
31.75 
±0.32
15.87 
±0.24 
××/⊗⊗
26.92 
±0.35
12.59 
±0.24 
××/⊗⊗
At 6 months 
postpartum/6 months 
old
21.67 ± 0.24 7.52 ± 0.26 
××/⊗⊗
24.10 ± 
0.26
8.49 
±0.20 
××/⊗⊗
25.42 
±0.25
7.23 
±0.22 
××/⊗⊗
20.79 
±0.34
8.91 
±0.20 
××/⊗⊗
25.19 
±0.33
11.22 
±0.19 
××/⊗⊗
19.24 
±0.35
7.94 
±0.18 
××/⊗⊗
Note: M—mother; I—infant.
▲: p < 0.05—for differences between infants from different observation groups.
×: p < 0.05; ××: p < 0.01—for differences between “mother-infant” groups.
⊗: p < 0.05; ⊗⊗: p < 0.01—for infants’ intra-group differences versus at birth data.
Table 9. State of transplacental post-vaccination immunity in “mother-infant” pairs following vaccination against influenza using “Grippol® Plus” vaccine.
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4. Conclusions
1. Different underlying diseases diagnosed in women of reproductive age are not an im-
pediment to influenza vaccination during pregnancy.
2. Influenza vaccination during pregnancy using Russian-made polymer-subunit monova-
lent and trivalent vaccines (“MonoGrippol Plus” and “Grippol® Plus”) in 58.1–60.0% of 
cases is accompanied by asymptomatic post-vaccination period. The frequency of sys-
temic (generalized) post-vaccination reactions in immunized women (6.9–14.0%) does 
not differ significantly from that in placebo control group (10.2–12.2%).
3. Administration of adjuvanted vaccines to pregnant women does not cause disturbances 
of their metabolic homeostasis, hormonal profile, and cytokine profile.
4. Vaccination of pregnant women against influenza does not affect trophoblast function 
and fetal growth. Vaccination neither bears the risk of miscarriage nor influences the pat-
tern and duration of breastfeeding.
5. Considering that safety of adjuvanted influenza vaccines has been proven by clinical and 
laboratory investigations, additional safety studies in pregnant women before and post-
vaccination are redundant.
6. Babies born to mothers vaccinated against influenza with adjuvanted vaccines (“Mon-
oGrippol Plus” and “Grippol® Plus”) have a high level of physiological maturity. The 
basic parameters of physical and neuropsychological development in the early postnatal 
period in such infants do not differ from those of infants from control group.
7. Infants born to women vaccinated during pregnancy with influenza vaccines are 1.8 
times less likely to develop non-influenza respiratory infections within the first 6 months 
of life as compared to infants born to unvaccinated mothers.
8. Administration of adjuvanted trivalent vaccine to pregnant women elicits a pronounced 
immune response to influenza vaccine strains A and B that fully meets the CPMP criteria 
for seroprotection levels: A/H1N1/v—82.0%, A/H3N2/—88.0% and B—88.3%.
9. Women vaccinated with the polymer-subunit vaccine in the second trimester of preg-
nancy benefit from higher seroprotection level and longer retention time of influenza-
specific antibodies.
10. Protective titers of transplacental antibodies to different influenza virus strains are found 
in 52.3–68.9% of infants that is comparable to control figures. Higher levels of protec-
tive antibodies to different influenza virus strains are found in infants whose mothers 
have been vaccinated with adjuvanted vaccine “Grippol® Plus” in the second trimester 
of pregnancy.
11. Analysis of mother-infant pairs showed a direct correlation in levels of post-vaccination 
IgG influenza-specific antibodies between mother and infant. However, after 3 months, 
protective antibodies to influenza virus strains were detectable in 14.2–36.1% of infants 
followed by their complete disappearance at 6 months of life versus 57.1–71.4% (3 months) 
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and 48.1–65.4% (6 months) in their mothers. This observation provides substantiation that 
vaccination against influenza in high-risk infants shall start at the age of 6 months.
12. The results obtained allow us to recommend the “Grippol® Plus” vaccine for use in 
healthcare practice for specific prevention of seasonal influenza in pregnant women and 
their offspring up to age 6 months inclusive, using a single-dose vaccination schedule.
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